Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Clinical management of thrombocytopenia in cirrhosis].
Li JP, Tan Y, Sun H, Lin GQ, Chen BB, Wu Y, Xie ZW, Wang YP, Lu AQ, Guan YJ. Li JP, et al. Among authors: guan yj. Zhonghua Gan Zang Bing Za Zhi. 2024 Jun 20;32(6):489-492. doi: 10.3760/cma.j.cn501113-20240326-00158. Zhonghua Gan Zang Bing Za Zhi. 2024. PMID: 38964889 Review. Chinese.
[A phase II, single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of sofosbuvir combined with ribavirin in patients with genotype 2 chronic hepatitis C virus infection].
Gao YH, Li GM, Jin QL, Zhao YR, Jia ZS, Mao XR, Yang YF, Shang J, Wang GC, Xie W, Wu SM, Zhang MX, Hou JL, Li DL, Nan YM, Guan YJ, Zhu CX, Yuan YZ, Wei L. Gao YH, et al. Among authors: guan yj. Zhonghua Gan Zang Bing Za Zhi. 2019 May 20;27(5):352-357. doi: 10.3760/cma.j.issn.1007-3418.2019.05.006. Zhonghua Gan Zang Bing Za Zhi. 2019. PMID: 31177659 Clinical Trial. Chinese.
Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China.
Xu X, Feng B, Guan Y, Zheng S, Sheng J, Yang X, Ma Y, Huang Y, Kang Y, Wen X, Li J, Tan Y, He Q, Xie Q, Wang M, An P, Gong G, Liu H, Ning Q, Hua R, Ning B, Xie W, Zhang J, Huang W, Yang Y, Lin M, Zhao Y, Yu Y, Jia J, Yang D, Chen L, Ye Y, Nan Y, Gong Z, Zhang Q, Hu P, Wang F, Li Y, Li D, Jia Z, Hou J, Chen C, Wu JJ, Wei L. Xu X, et al. J Clin Transl Hepatol. 2019 Sep 28;7(3):213-220. doi: 10.14218/JCTH.2019.00033. Epub 2019 Sep 30. J Clin Transl Hepatol. 2019. PMID: 31608212 Free PMC article.
Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China.
Hua R, Kong F, Li G, Wen X, Zhang Y, Yang X, Meng C, Xie W, Jiang Y, Wang X, Han X, Huang Y, Mao Q, Wang J, Guan Y, Chen J, Ma Y, Xiong Q, Ma H, Yan X, Rao H, Zhao Y, Sun T, Zhu L, Mao X, Lian J, Deng G, Xin Y, Wang Y, Ye Y, Xu B, Gao H, Tan Y, Li D, Yang D, Su M, Zhang X, Min J, Shi X, Wei L, Niu J. Hua R, et al. Infect Dis Ther. 2023 Nov;12(11):2595-2609. doi: 10.1007/s40121-023-00872-4. Epub 2023 Oct 19. Infect Dis Ther. 2023. PMID: 37856013 Free PMC article.
149 results